

DRUG DETERMINATION POLICY

Title: DDP-12 TNF Inhibitors

Effective Date: 06/04/2019



Physicians Health Plan
PHP Insurance Company
PHP Service Company

Important Information - Please Read Before Using This Policy

The following policy applies to health benefit plans administered by PHP and may not be covered by all PHP plans. Please refer to the member's benefit document for specific coverage information. If there is a difference between this general information and the member's benefit document, the member's benefit document will be used to determine coverage. For example, a member's benefit document may contain a specific exclusion related to a topic addressed in a coverage policy.

Benefit determinations for individual requests require consideration of:

1. The terms of the applicable benefit document in effect on the date of service.
2. Any applicable laws and regulations.
3. Any relevant collateral source materials including coverage policies.
4. The specific facts of the particular situation.

Contact PHP Customer Service to discuss plan benefits more specifically.

1.0 Policy:

This policy describes the determination process for coverage of specific drugs.

This policy does not guarantee or approve benefits. Coverage depends on the specific benefit plan. Drug Determination Policies are not recommendations for treatment and should not be used as treatment guidelines.

2.0 Background or Purpose:

Tumor Necrosis Factor (TNF) Inhibitors are specialty drugs indicated for a number of diagnoses and are associated with significant toxicity. These criteria were developed and implemented to ensure appropriate use for the intended diagnoses and mitigation of toxicity, if possible.

3.0 Clinical Determination Guidelines:

Document the following with chart notes:

- I. General Criteria & Information
 - A. Other therapies: contraindicated, failed or had significant adverse effects with 2 preferred TNF Inhibitors
 1. Rx (self-injected): Enbrel SC, Humira SC.
 2. Medical (infused): Inflectra IV, Remicade IV, Simponi Aria IV.
 3. Grandfather status: patients currently on non-preferred TNF inhibitors may continue therapy.
 4. Required site-of-care as determined by the Health Plan.
 5. Excluded agents:
 - a. All preferred products are contraindicated, failed or resulted in significant adverse effects.

B. Familial history, past or concomitant disease states

1. Cancer: family history, past or concomitant cancer is not a contraindication for TNF therapy.

C. Dosage regimen

1. Within the FDA approved labeling: titrate up based on symptoms and disease severity.
2. Greater than the FDA approved labeling: base on disease symptoms and severity (except infliximab and adalimumab - see Appendix II).

D. Approval

1. Initial: six months.
2. Re-approval: one year (decreased or sustained reduction in disease activity).

II. Therapeutic Drug Monitoring: infliximab and adalimumab

A. Indication: requests for dosage regimens greater than FDA-approved labeling.

1. Infliximab: $\geq 10\text{mg/Kg}$ every eight weeks (or equivalent dosage at a different frequency) or $\geq 1000\text{mg}$.
2. Adalimumab: $\geq 40\text{mg}$ twice monthly.

B. Criteria (all below):

1. Patient has received three stable maintenance doses.
2. Trough drug and antibody levels drawn just prior to drug infusion (verify timing).
3. Determine coverage based on drug and antibody level.

Infliximab (Remicade)			
Antibody Titer (quantitation limit < 22 ng/mL)	Drug Level (quantitative limit < 0.4 $\mu\text{g/ml}$)		
	$\leq 3 \mu\text{g/ml}$	>3 - 10 $\mu\text{g/ml}$	>10 $\mu\text{g/ml}$
Low: 22 - 200 ng/mL	↑ dose	Maintain dose	↓ or maintain dose
Intermediate: 201 - 1,000 ng/mL	↑ dose	Variable	Switch agent
High: >1,001 ng/mL	Switch agent	Switch agent	Switch agent
Adalimumab (Humira)			
Antibody Titer (quantitation limit < 25 ng/mL)	Drug level (quantitative limit <0.6 $\mu\text{g/ml}$)		
	$\leq 5 \mu\text{g/ml}$	>5 - 8 $\mu\text{g/ml}$	>8 $\mu\text{g/ml}$
Low: 25 - 200 ng/mL	↑ dose	Maintain dose	↓ or maintain dose
Intermediate: 201 - 1,000 ng/mL	↑ dose	Variable	Switch agent
High: >1,001 ng/mL	Switch agent	Switch agent	Switch agent

4. Determination

- a. Increase or maintain dose: approve current; or requested increased dose or frequency.
- b. Decrease or maintain dose: approve previously approved dose.
- c. Variable: approve current; or requested increased dose or frequency.

d. Switch agent: deny.

III. Inflammatory Bowel Disease

A. Age: ≥ 6 years.

B. Prescriber: gastroenterologist.

C. Crohn's Disease (CD) or ulcerative colitis (UC).

1. Diagnosis and severity: moderate to severe CD or UC.
2. Other therapies: contraindicated, failed or significant adverse effects (one of both below):
 - a. Conventional therapies (four months.): mesalamine, metronidazole.
 - b. DMARD (four months): CD - azathioprine, methotrexate; UC - sulfasalazine.
3. Exclude: Cimzia SC (certolizumab), Renflexis IV (infliximab).
4. Dosage regimen
 - a. Humira SC (adalimumab):
 - i. Adults: 160 mg week 0, 80mg week 2, then 40mg every 2 weeks.
 - ii. Pediatric CD: 17 to < 40Kg - 80mg (2 x 40mg day 1), 40mg day 15 then 20mg every two weeks.
 - b. Remicade or Inflectra IV (infliximab): 5mg/Kg at 0, 2, 6 weeks, then 5mg/Kg every 8 weeks.

D. Exceptions: skipping the requirements of "2. *Other therapies*" are allowed if patient exhibits severe or fulminant disease (See Appendix I).

IV. Inflammatory Joint Diseases

A. Prescriber: rheumatologist

B. Rheumatoid Arthritis (RA)

1. Diagnosis and severity: moderate to severe.
 - a. Other therapies: contraindicated, failed or significant adverse effects with 2 first line DMARDs (4 months): methotrexate, leflunomide, hydroxychloroquine, sulfasalazine.
2. Exclude: Cimzia SC (certolizumab), Renflexis IV (infliximab), Simponi SC (golimumab)
3. Dosage regimen: suggested in combination with methotrexate.
 - a. Enbrel SC (etanercept): 50mg per week or 25mg 2x per week.
 - b. Humira SC (adalimumab): 40mg every two weeks.
 - c. Remicade or Inflectra IV (infliximab): 5mg/Kg at 0, 2, 6 weeks then every 8 weeks.
 - d. Simponi Aria IV (golimumab): 2mg/Kg at 0, 4 then every 8 weeks.

C. Psoriatic Arthritis (PA)

1. Diagnosis and severity: active PA with ≥ 5 swollen and ≥ 5 tender joints.
2. Other therapies: Contraindicated, failed or significant adverse effects from two below (dependent on location):
 - a. Peripheral disease: first^t line DMARD therapy (four months) - methotrexate, leflunomide, sulfasalazine.
 - b. Axial disease, enthesitis, dactylitis and uveitis (four months): NSAIDs
3. Exclude: Cimzia SC (certolizumab), Renflexis IV (infliximab), Simponi SC (golimumab).

4. Dosage regimen.
 - a. Enbrel SC (etanercept): 50mg per week or 25mg two times per week.
 - b. Humira SC (adalimumab): 40mg every two weeks .
 - c. Remicade or Inflectra IV (infliximab): 5mg/Kg at 0, 2, 6 weeks, then 5mg/Kg every 8 weeks.
 - d. Simponi Aria IV (golimumab): 2mg/Kg at 0, 4 then every 8 weeks.

D. Ankylosing Spondylitis (AS)

1. Diagnosis and severity: active AS.
2. Other therapies: contraindicated, failed or significant adverse effects with two first line DMARDs (four months): methotrexate, leflunomide, sulfasalazine.
3. Exclude: Cimzia SC (certolizumab), Renflexis IV (infliximab), Simponi SC (golimumab)
4. Dosage regimen.
 - a. Enbrel SC (etanercept): 50mg per week or 25mg two times per week.
 - b. Humira SC (adalimumab): 40mg every two weeks.
 - c. Remicade/Inflectra IV (infliximab): 5mg/Kg at 0, 2, 6 weeks then 5mg/Kg every 8 weeks.
 - d. Simponi Aria IV (golimumab): 2mg/Kg at 0, 4 then every 8 weeks.

E. Juvenile Idiopathic Arthritis (JIA)

1. Age: ≥ 4 years.
2. Diagnosis and severity: moderate to severe active polyarticular JIA.
3. Other therapies: contraindicated, failed or significant adverse effects with two first line DMARDs (four months): Anakinra, MTX, leflunomide.
4. Dosage regimen.
 - a. Enbrel SC (etanercept): $< 31\text{Kg}$ - 0.8mg/Kg per week; $\geq 31\text{-}62\text{Kg}$ - 0.4mg/Kg two times per week.; $\geq 63\text{Kg}$ - 50mg per week.
 - b. Humira SC (adalimumab): $\geq 30\text{Kg}$ - 40mg every 2 weeks.; 15-30Kg - 20mg every two weeks.

IV. Dermatological Diseases

A. Prescriber: dermatologist.

B. Plaque psoriasis (PP).

1. Diagnosis and severity: moderate to severe chronic PP.
 - a. Duration: chronic PP > 6 months.
 - b. Severity.
 - Body surface area (BSA): $\geq 10\%$; OR
 - Severe at localized sites and associated with significant functional impairment (e.g., involvement of high-impact and difficult to treat sites (face, scalp, palms, soles, flexures and genitals).
2. Other therapies: contraindicated, failed or significant adverse effects with two of category a and one of b:

- a. Local therapies (four months.): topical (steroids, vitamin- D analogues, coal tar, dithranol), phototherapy, photochemotherapy.
- b. Systemic therapy (four months): cyclosporine, methotrexate.
- 3. Excluded: Cimzia SC (certolizumab), Renflexis IV (infliximab).
- 4. Dosage regimen.
 - a. Enbrel SC (etanercept): 50mg two times per week for three months then 50mg per week.
 - b. Humira SC (adalimumab): 80mg at week 0, 40mg at week 1; then 40mg every 2 weeks.
 - c. Remicade or Inflectra IV (infliximab): 5mg/Kg at 0, 2, 6 weeks then 5mg/Kg every 6 weeks.

C. Hidradenitis Suppurativa (HS)

- 1. Diagnosis and severity: moderate to severe chronic HS.
- 2. Other therapies: contraindicated, failed or significant adverse effects with one of both below:
 - a. Local therapies (four months): topical clindamycin (mild diagnosis), intra-lesional triamcinolone.
 - b. Systemic therapies (four months): clindamycin plus rifampicin (both 300mg bid po), acitretin, finasteride or spironolactone (female patients), cyclosporine, dapsone.
- 3. Dosage Regimen.
 - a. Humira SC (adalimumab): 160mg (4 times 40mg day or 2 times 40mg day 1 and 2), 80mg day 15, then 40mg per week.

V. Ocular

A. Prescriber: ophthalmologist

B. Uveitis

- 1. Age: ≥ 2 years.
- 2. Diagnosis and severity: non-infectious intermediate, posterior, and panuveitis (not anterior).
- 3. Other therapies: contraindicated, failed or significant adverse effects (one of each below):
 - a. Topical: difluprednate 0.5%.
 - b. Ocular injection: periocular or intraocular triamcinolone or intraocular dexamethasone.
 - c. Systemic: cyclosporine, methotrexate, azathioprine, mycophenolate, tacrolimus.
- 4. Dosage regimen: Humira SC (adalimumab).
 - a. Adult: 80mg times 1, then week 1 40mg, then 40mg every 2 weeks.
 - b. Pediatrics: 10 to <15Kg - 10mg every two weeks; 15 to < 30Kg - 20mg every two weeks; ≥ 30 Kg – 40mg every two weeks.

4.0 Coding:

AFFECTED CODES			
HCPCS Code	Brand name	Generic name	Billing units (1u)
J3358	Stelara		1mg
J3262	Actemra IV		1mg
0078-0069-98	Cosentyx 2-pack syringe		
Q5103	Inflectra		10mg
J1745	Remicade		10mg
J1602	Simponi Aria		

NON-COVERED CODES		
Code	Description	Benefit Plan Reference/Reason
J0135	Humira	Prior authorization/approval required. If approved, it must be billed on the pharmacy side.
J1438	Enbrel	Prior authorization/approval required. If approved, it must be billed on the pharmacy side.
J8610	Methotrexate oral 2.5mg	Prior authorization/approval required. If approved, it must be billed on the pharmacy side.
Q5104	Renflexis	Preferred agents are Inflectra, Remicade

5.0 References, Citations & Resources:

1. Lexicomp Online®, Lexi-Drugs®, Hudson, Ohio: Lexi-Comp, Inc.; Remicade, Enbrel, Humira, Simponi, Cimzia, Stelara, accessed July 2018.
2. Hidradenitis Suppurativa: A review of cause & treatment. Current opinions in Infectious disease 2011;24;118-123.
3. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy 2010; 30(4);339-53.
4. Agency for Healthcare research and Quality (AHRQ) National Guideline Clearing House accessed April 2017:
 - a. Clinical practice guidelines for the treatment of patient's w axial spondyloarthritis & psoriatic arthritis.
 - b. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of JIA: recommendations for medical therapy of children w systemic JIA.
 - c. 2012 update of the 2008 American College of Rheumatology recommendation for the use of disease-modifying anti-rheumatic drugs & biologic agents in the treatment of rheumatoid arthritis.
 - d. Ulcerative Colitis. Management in adults, children and young people.
 - e. American Gastroenterological Association institute guidelines on the use of thiopurines, methotrexate and anti-TNF biological drugs for the induction and maintenance of remission in inflammatory Crohn's disease.

- f. Psoriasis: The assessment & management of psoriasis.
6. Trough concentrations of infliximab guide dosing for patients with IBD. *Gastroenterology*.2015;148;1133-9.
 7. 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: Part 1: Diagnosis and medical management. *Journal of Crohn's and Colitis*. 2017;11:3-25.
 8. British Association of Dermatologists guidelines for the biological therapy for psoriasis 2017;177(3):628-36.
 9. Clinical Practice Guidelines for the treatment of patients with axial spondyloarthritis and psoriatic arthritis. Madrid, (Spain): Spanish Society of Rheumatology (SER);2015.
 10. Vaughn BP, et al *Gastroenterol* 2016;150(4)s105-s106.
 11. Current practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Rheumatoid Arthritis. *The Drug Monit* 2017;39(4): 364-367.
 12. Labcorp <https://www.labcorp.com/test-menu/18766/adalimumab-concentration-and-anti-adalimumab-antibody--serial-monitor> accessed on November 6, 2018.
 13. Uptodate Uveitis: Etiology, clinical Manifestations, and diagnosis; Uveitis: Treatment. Accessed November 2018.6.0.

6.0 Appendices:

Appendix I- Definitions of Disease Activity in Crohn's Disease and Ulcerative colitis⁷

Supplementary Table 1. International Definitions of Disease Activity in Crohn's Disease and Ulcerative Colitis

Crohn's disease (international definitions based on CDAI parameters¹)

ACG ²	Symptomatic remission CDAI <150 Asymptomatic/without symptomatic inflammatory sequelae May have responded to medical or surgical therapy and have no residual active disease Does not include patients who require corticosteroids	Mild-moderate CDAI 150-220 Ambulatory Able to tolerate oral alimentation without manifestations of dehydration, systemic toxicity (high fevers, rigors, and prostration), abdominal tenderness, painful mass, intestinal obstruction, or >10% weight loss	Moderate-severe CDAI 220-450 Failed to respond to treatment for mild-moderate disease <i>or</i> Has more prominent symptoms of fever, significant weight loss, abdominal pain or tenderness, intermittent nausea or vomiting (without obstructive findings), or significant anemia	Severe/fulminant CDAI >450 Persistent symptoms despite treatment with corticosteroids/biologics as outpatients <i>or</i> Has high fevers, persistent vomiting, intestinal obstruction, significant peritoneal signs, cachexia, or abscess
ECCO ³	Symptomatic remission CDAI <150	Mild CDAI 150-220 Ambulatory Eating and drinking <10% weight loss No obstruction, fever, dehydration, abdominal mass, or tenderness CRP increased above ULN	Moderate CDAI 220-450 Intermittent vomiting or weight loss >10% Treatment for mild disease ineffective or tender mass No overt obstruction CRP increased above ULN	Severe CDAI >450 Cachexia or evidence of obstruction/abscess Persistent symptoms despite intensive treatment CRP increased
Ulcerative colitis (international definitions based on Truelove-Witts criteria) ⁴				
ACG ⁵	Symptomatic remission	Mild <4 stools/d (with or without blood) No systemic signs of toxicity Normal ESR	Moderate ≥4 stools/d Minimal signs of toxicity	Severe ≥6 bloody stools/d Signs of toxicity (fever, tachycardia, anemia) Increased ESR
				Fulminant ≥10 stools/d Continuous bleeding Toxicity Abdominal tenderness and distension Blood transfusion requirement Colonic dilation on abdominal plain films
ECCO ⁶	Symptomatic remission <4 stools/d without bleeding or urgency	Mild <4 bloody stools/d Pulse <90 bpm Temperature <37.5°C Hemoglobin >11.5 g/dL ESR <20 mm/h or normal CRP	Moderate^a ≥4 bloody stools/d <i>if</i> Pulse ≤90 bpm Temperature ≤37.8°C Hemoglobin ≥10.5 g/dL ESR ≤30 mm/h or CRP ≤30 mg/dL	Severe^b ≥6 bloody stools/d <i>and</i> Pulse >90 bpm Temperature >37.8°C Hemoglobin <10.5 g/dL ESR >30 mm/h or CRP >30 mg/dL

Appendix II: FDA Approved Indications

FDA Approved Indications	Rheumatoid Arthritis (RA)	Psoriatic Arthritis (PA)	Ankylosis Spondylitis (AS)	Juvenile Idiopathic Arthritis (JIA)	Crohn's Disease (CD) **	Ulcerative Colitis (UC)	Plaque Psoriasis (PP)
Preferred TNF Inhibitors							
Enbrel SC	X	X	X	X			X
Humira SC*	X	X	X	X	X	X	X
Inflectra IV	X	X	X		X	X	X
Remicade IV	X	X	X		X	X	X
Simponi Aria IV	X	X	X			X	
Excluded TNF Inhibitors							
Cimzia SC	X	X	X		X		X
Renflexis IV	X	X	X		X	X	X
Simponi SC	X	X	X			X	

* Humira is the only TNF Inhibitor FDA approved for use in Hidradenitis suppurativa and Uveitis

** Humira, Inflectra, Remicade and Renflexis also approved for pediatric CD

Appendix III. Monitoring and Patient Safety

Drug	Adverse Reactions	Monitoring	REMS
Enbrel SC etanercept SC	<ul style="list-style-type: none"> • CNS: HA (17-19%) • Derm: 3-13% • Infection (50-81%) • Immunologic: antibodies (15%), +ANA (11%), • Local: injection site Rx (14-43%) • Resp: non-URI (21-54%), URI (38-65%), rhinitis (12%) 	<ul style="list-style-type: none"> • Infection: watch for signs & symptoms (s/sx); D/C drug if serious (Black box) • TB: test prior to tx; watch for s/sx 	None Needed
Humira SC adalimumab	<ul style="list-style-type: none"> • CNS: HA (12%) • Derm: rash (6-12%) • Immunologic: antibodies (3-16%) • Infection (1.4-6.7 event/person yrs) • Local: injection site rx (12-20%) • Resp: sinusitis (11%), URI (17%) 	<ul style="list-style-type: none"> • UC or dysplasia/colon CA: check intermittently • CHF: watch for s/sx; D/C if 	

Drug	Adverse Reactions	Monitoring	REMS
Remicade IV infliximab	<ul style="list-style-type: none"> • CNS: headache (18%) • GI: abd pain (12-26%), diarrhea (12%), nausea (21%) • Hepatic: ↑ LFT (50%) • Immunologic: drug antibodies (10-51%), +ANA (50%) • Infection: infection (27-36%), • Resp: cough (12%), pharyngitis (12%), sinusitis (14%), URI (32%) 	<p>worse</p> <ul style="list-style-type: none"> • HBV: watch for s/sx 	
Simponi Aria IV golimumab	<ul style="list-style-type: none"> • Immunologic: antibodies (4%), +ANA (4%), • Infections (27-28%), • Resp: URI (13-16%) 		

*Pregnancy category B

7.0 Revision History:

Original Effective Date: July 12, 2006

Last Approval Date: 06/04/2019

Next Review Date: 06/04/2020

Revision Date	Reason for Revision
4/19	Moving to new format